Illumina continued to rebuff Roche's acquisition attempts this week, citing the growing adoption of its sequencing platforms in the clinical market as evidence for growth potential that is not adequately reflected by Roche's current offer.

Roche, meanwhile, argued that Illumina has not provided "any quantifiable evidence or projections" for when or how the predicted growth will be realized.

Roche increased its hostile takeover bid for Illumina last week, from $44.50 to $51 per share (GWDN 3/29/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.